Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomized, controlled study.

Détails

ID Serval
serval:BIB_5736
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomized, controlled study.
Périodique
Critical Care Medicine
Auteur⸱e⸱s
Pichard C., Kyle U., Chevrolet J.C., Jolliet P., Slosman D., Mensi N., Temler E., Ricou B.
ISSN
0090-3493
Statut éditorial
Publié
Date de publication
1996
Volume
24
Numéro
3
Pages
403-413
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't ; Review Publication Status: ppublish
Résumé
OBJECTIVE: To evaluate the benefit of recombinant human growth hormone administration on muscle strength and duration of weaning in critically ill patients undergoing prolonged mechanical ventilation. DESIGN: Prospective, randomized, controlled, single-blind study. SETTING: Intensive care unit. Patients: Twenty patients requiring > or = 7 days of mechanical ventilation for acute respiratory failure. INTERVENTION: Random assignment to receive either 0.43 IU (approximately 0.14 mg) recombinant growth hormone/kg body weight/day (treated group), or saline (nontreated group) for 12 days. MEASUREMENTS AND MAIN RESULTS: Nutritional support was guided by indirect calorimetry. Cumulative nitrogen balance was positive throughout the study period in the treated group 17.3 (44.9 +/- 17.3[SEM] g/12 days) vs. the nontreated group (-65.8 +/- 11.8 g/12 days) (p<.0001). Despite similar initial plasma concentrations, recombinant growth hormone supplementation resulted in marked increases in growth hormone, insulin like growth factor-1, and insulin concentrations (p<.05, .02, and .0001, respectively, vs. nontreated group). Body impedance determined net fat-free mass increased in the treated group (0.8 +/- 0.6 kg) vs. the nontreated group (-1.1 +/- O.5 kg) (p<.03). Initial peripheral muscle function, assessed by computer-controlled electrical stimulation of the adductor pollicis, was similarly lower in treated and nontreated groups than sex and age-matched normal controls, and decreased further during the study period. Arterial blood gases, cumulative total mechanical ventilation time, and number of hrs/day of mechanical ventilation during weaning were similar in both patient groups. Only three of the ten patients in each group were weaned from mechanical ventilation by day 12. CONCLUSIONS: Daily administration of recombinant growth hormone in mechanically ventilated patients with acute respiratory failure promotes a marked nitrogen retention. However, this reaction is accompanied neither by an improvement in muscle strength nor by a shorter duration of ventilatory supports.
Mots-clé
Acute Disease, Aged, Combined Modality Therapy, Female, Growth Hormone/therapeutic use, Humans, Male, Middle Aged, Nutritional Support, Prospective Studies, Recombinant Proteins/therapeutic use, Respiration, Artificial, Respiratory Insufficiency/physiopathology, Respiratory Insufficiency/therapy, Respiratory Muscles/drug effects, Respiratory Muscles/physiopathology
Pubmed
Web of science
Création de la notice
19/11/2007 13:42
Dernière modification de la notice
20/08/2019 15:11
Données d'usage